Middle East
The British Premium Skin Care Brand will join the Group’s Luxe Division
Clichy, 9 June 2025 – L’Oréal Groupe today announced that it has signed an agreement to acquire a majority stake in the British skincare brand Medik8.
As part of the transaction, Inflexion, a leading European mid-market private equity firm, will remain a minority shareholder. The Founder will continue to serve on the board, with the current management committee also remaining in place to ensure continuity.
Founded by scientist Elliot Isaacs, Medik8 is best known for its iconic Crystal Retinal serum and its trademark CSA Philosophy©: Vitamin C and Sunscreen by Day, Vitamin A by night. Driven by scientific research and innovation, the brand offers ingredient-led premium skincare to deliver “results without compromise”. Still true to its professional origins, the brand has also evolved towards a diversified omni-channel sales mix across the most prominent online and offline retailers in Europe, with a growing presence in the US.
This acquisition further strengthens L’Oréal’s Luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth.
“We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,” explained Cyril Chapuy, President of L’Oréal LUXE. “We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”
“This is an exciting day for Medik8,” said Simon Coble, CEO of Medik8. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”
L’Oréal will start consolidating Medik8 sales from the date of the closing of the transaction. As part of the agreement, L’Oréal has also secured rights to buyout in full the minority shareholders.
The transaction is expected to be completed in the next few months after regulatory approvals and other customary conditions.
“This news release does not constitute an offer to sell, or a solicitation of an offer to buy L’Oréal shares. If you wish to obtain more comprehensive information about L’Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our website www.loreal-finance.com.
This news release may contain some forward-looking statements. While the Company believes that these statements are based on reasonable assumptions as of the date of publication of this press release, they are by nature subject to risks and uncertainties which may lead to a discrepancy between the actual figures and those indicated or suggested in these statements.”
About L’Oréal Groupe
For 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential, inclusive, ethical, generous and committed to social and environmental sustainability. With our broad portfolio of 37 international brands and ambitious sustainability commitments in our L’Oréal for the Future programme, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.
With more than 90,000 committed employees, a balanced geographical footprint and sales across all distribution networks (e-commerce, mass market, department stores, pharmacies, perfumeries, hair salons, branded and travel retail), in 2024 the Group generated sales amounting to 43.48 billion euros. With 21 research centers across 13 countries around the world and a dedicated Research and Innovation team of over 4,000 scientists and 8,000 Digital talents, L’Oréal is focused on inventing the future of beauty and becoming a Beauty Tech powerhouse.
More information on https://www.loreal.com/en/mediaroom
L'ORÉAL CONTACTS
Switchboard
+33 (0) 1 47 56 70 00
Individual shareholders and market authorities
Pascale Guerin
+33 (0)1 49 64 18 89
[email protected]
Investor relations
Eva Quiroga
+33 (0)7 88 14 22 65
[email protected]
Journalists
Brune Diricq
+33 (0)6 63 85 29 87
[email protected]
Christine Burke
+33 (0)6 75 54 38 15
[email protected]
For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, the website for shareholders and investors, www.loreal-finance.com or the L'Oréal Finance app; alternatively, call +33 (0)1 40 14 80 50.
Follow us on LinkedIn @L'Oréal
Follow us on Instagram @lorealgroupe
www.loreal.com